US regulators to weigh controversial peptides backed by RFK Jr

ahead of this week’s meeting, the agency said there is little evidence supporting the safety or effectiveness of the seven compounds under review, citing inadequate human clinical trials and concerns about their quality, stability and consistency.

But despite those concerns, demand has continued to soar. The compounds are marketed through wellness clinics continue reading …